Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys.

OBJECTIVE To evaluate the effects of 8-iso prostaglandin E2 (8-iso PGE2; prosta-5,13-dien-1-oic acid,11,15-dihydroxy-9-oxo-,[5Z,8beta-11X,13E,15 S]-) on the intraocular pressure (IOP), outflow facility, and aqueous humor flow rates in normal monkeys and monkeys with glaucoma. METHODS The IOP was measured before and as long as 6 hours after the topical application of 8-iso PGE2 to 1 eye of 6 normal monkeys and to the glaucomatous eye of 8 monkeys with unilateral laser-induced glaucoma. The pupil diameter was measured at the same times as the IOP measurements in the normal monkeys. Tonographic outflow facility and fluorophotometric flow rates of aqueous humor were measured in 6 normal monkeys before and after drug treatment. RESULTS In normal monkeys, a single dose of 0.1% 8-iso PGE2 reduced (P<.01) the IOP for 4 hours in the treated eyes with a maximum (mean +/- SEM) reduction of 3.2 +/- 0.2 mm Hg, compared with the contralateral control eyes. The pupil size was smaller (P<.01) in the treated eyes by as much as 1.0 +/- 0.2 mm for 4 hours. In 8 glaucomatous monkey eyes, the application of 0.05% and 0.1% 8-iso PGE2 reduced the IOP (P<.01) for as long as 2 and 5 hours, respectively. The maximum reduction in the IOP was 4.6 +/- 0.8 mm Hg (0.05%) and 6.0 +/- 0.8 mm Hg (0.1%) compared with baseline measurements. The magnitude and duration of the ocular hypotensive effect were enhanced with twice-a-day administration for 5 consecutive days. Outflow facility in normal monkey eyes was increased (P<.05) by 48% in the treated eyes, and aqueous humor flow was unchanged (P>.10), compared with vehicle-treated contralateral control eyes. Mild eyelid edema, conjunctival edema, hyperemia, and discharge appeared in some eyes treated with the 0.1% drug concentration. CONCLUSIONS The use of 8-iso PGE2 reduces the IOP in both normal and glaucomatous monkey eyes. An increase in outflow facility appears to account for most of the IOP reduction in normal monkeys. CLINICAL RELEVANCE The application of 8-iso PGE2 may have potential for the treatment of glaucoma as an outflow facility-increasing drug.

[1]  Y. Kitazawa,et al.  A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. , 1998, Japanese journal of ophthalmology.

[2]  R. Brubaker,et al.  Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. , 1997, Survey of ophthalmology.

[3]  J. Morrow,et al.  The isoprostanes. Current knowledge and directions for future research. , 1996, Biochemical pharmacology.

[4]  Camras Cb.  Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. , 1995 .

[5]  C. Camras.  Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. , 1995, Advances in prostaglandin, thromboxane, and leukotriene research.

[6]  A. Alm,et al.  PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. , 1991, Archives of ophthalmology.

[7]  R. Eglen,et al.  EP3, but not EP2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure. , 1990, Investigative ophthalmology & visual science.

[8]  S. Podos,et al.  Effects of prostaglandins F2 alpha, A2, and their esters in glaucomatous monkey eyes. , 1990, Investigative ophthalmology & visual science.

[9]  P. Kaufman,et al.  The effect of prostaglandin F2α on trabecular outflow facility in cynomolgus monkeys , 1990 .

[10]  J. Rohen,et al.  Age-related changes of the ciliary muscle in comparison with changes induced by treatment with prostaglandin F2α. An ultrastructural study in rhesus and cynomolgus monkeys , 1990, Mechanisms of Ageing and Development.

[11]  E. Tamm,et al.  [Electron microscopy and immunohistochemical studies of the intraocular pressure lowering effect of prostaglandin F2 alpha]. , 1990, Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[12]  J. Rohen,et al.  Age-related changes of the ciliary muscle in comparison with changes induced by treatment with prostaglandin F2 alpha. An ultrastructural study in rhesus and cynomolgus monkeys. , 1990, Mechanisms of ageing and development.

[13]  S. Podos,et al.  Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. , 1989, Ophthalmology.

[14]  P. Kaufman,et al.  Aqueous humor dynamics: how PGF2 alpha lowers intraocular pressure. , 1989, Progress in clinical and biological research.

[15]  E. Tamm,et al.  Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. , 1988, Experimental eye research.

[16]  A. Flach,et al.  Topical prostaglandin E2 effects on normal human intraocular pressure. , 1988, Journal of ocular pharmacology.